NNVC vs. APLT, BGM, INCR, MURA, GANX, PMVP, IKNA, MRSN, AVTE, and PWUP
Should you be buying NanoViricides stock or one of its competitors? The main competitors of NanoViricides include Applied Therapeutics (APLT), Qilian International Holding Group (BGM), InterCure (INCR), Mural Oncology (MURA), Gain Therapeutics (GANX), PMV Pharmaceuticals (PMVP), Ikena Oncology (IKNA), Mersana Therapeutics (MRSN), Aerovate Therapeutics (AVTE), and PowerUp Acquisition (PWUP). These companies are all part of the "pharmaceutical products" industry.
NanoViricides vs.
NanoViricides (NYSE:NNVC) and Applied Therapeutics (NASDAQ:APLT) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, earnings, community ranking, media sentiment, profitability, dividends, valuation, analyst recommendations and institutional ownership.
Applied Therapeutics received 80 more outperform votes than NanoViricides when rated by MarketBeat users. Likewise, 57.55% of users gave Applied Therapeutics an outperform vote while only 0.00% of users gave NanoViricides an outperform vote.
Applied Therapeutics has a consensus target price of $6.10, indicating a potential upside of 1,050.94%. Given Applied Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Applied Therapeutics is more favorable than NanoViricides.
NanoViricides' return on equity of -87.90% beat Applied Therapeutics' return on equity.
10.3% of NanoViricides shares are held by institutional investors. Comparatively, 98.3% of Applied Therapeutics shares are held by institutional investors. 4.6% of NanoViricides shares are held by insiders. Comparatively, 8.6% of Applied Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
In the previous week, Applied Therapeutics had 14 more articles in the media than NanoViricides. MarketBeat recorded 17 mentions for Applied Therapeutics and 3 mentions for NanoViricides. NanoViricides' average media sentiment score of 0.25 beat Applied Therapeutics' score of 0.15 indicating that NanoViricides is being referred to more favorably in the media.
NanoViricides has higher earnings, but lower revenue than Applied Therapeutics. NanoViricides is trading at a lower price-to-earnings ratio than Applied Therapeutics, indicating that it is currently the more affordable of the two stocks.
NanoViricides has a beta of 1.35, meaning that its share price is 35% more volatile than the S&P 500. Comparatively, Applied Therapeutics has a beta of 1.88, meaning that its share price is 88% more volatile than the S&P 500.
Summary
Applied Therapeutics beats NanoViricides on 12 of the 16 factors compared between the two stocks.
Get NanoViricides News Delivered to You Automatically
Sign up to receive the latest news and ratings for NNVC and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
NanoViricides Competitors List
Related Companies and Tools
This page (NYSE:NNVC) was last updated on 2/22/2025 by MarketBeat.com Staff
